Small Molecule Vif Inhibitors for HIV Replication Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for HIV infection are limited by the ability of the Virion Infectivity Factor (Vif) to counteract the antiviral activity of APOBEC3G and APOBEC3F, leading to reduced levels of these proteins and impaired host defense against HIV replication.

Innovation Solution

Development of small molecule Vif inhibitors that enhance Vif degradation, stabilize APOBEC3G and APOBEC3F, interfere with Vif-APOBEC3G interactions, and increase cellular concentrations of these proteins, thereby restoring the host's antiviral response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Vif is present during HIV replication, then HIV infectivity is maintained, but APOBEC3G and APOBEC3F are degraded leading to reduced host defense

Engineering Contradiction:

ImproveHIV infectivityVSAvoidAPOBEC3G and APOBEC3F protein levels

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent uses small molecule compounds as intermediaries to disrupt the interaction between Vif and APOBEC3G/APOBEC3F. These compounds bind to Vif and prevent it from recognizing and degrading the APOBEC proteins, thereby protecting host defense proteins while maintaining antiviral activity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful degradation activity of Vif into a beneficial effect by using compounds that exploit Vif's binding properties. The compounds bind to Vif's RNA binding domain, causing Vif to form non-functional complexes that cannot degrade APOBEC3G/APOBEC3F, thus transforming Vif's pathogenic function into a therapeutic target

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If APOBEC3G and APOBEC3F levels are increased to enhance host defense, then antiviral activity is improved, but HIV replication may be enhanced without Vif inhibition

Engineering Contradiction:

Improvehost antiviral defenseVSAvoidpotential enhancement of HIV replication

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by simultaneously increasing APOBEC3G/APOBEC3F levels and inhibiting Vif function with small molecule compounds. This dual approach ensures that any potential enhancement of HIV replication is preemptively blocked by Vif inhibition while the host defense proteins are present at elevated levels to maximize antiviral protection

Inventive Principle:

Principle #9Preliminary anti-action

3Stability of the object's composition

If small molecule Vif inhibitors are developed to block Vif function, then APOBEC3G and APOBEC3F stability is improved, but drug development complexity increases

Engineering Contradiction:

ImproveAPOBEC3G and APOBEC3F protein stabilityVSAvoiddrug development process

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent employs parameter changes by screening small molecule compounds with varying chemical structures, binding affinities, and molecular properties to identify optimal Vif inhibitors. By systematically modifying chemical parameters such as molecular weight, functional groups, and binding constants, the research identifies compounds that stabilize APOBEC3G/APOBEC3F while managing development complexity through structured optimization

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS7754773B2Composition and synthesis of new reagents for inhibition of HIV replication

Publication Date: 2010.07.13 UNIV OF MASSACHUSETTS

AI summary

The present invention provides compounds and compositions for inhibiting Vif and methods for treating viral infection, e.g., HIV infection.